XNAS
ASND
Market cap14bUSD
Sep 17, Last price
239.04USD
1D
-3.49%
1Q
3.56%
Jan 2017
1,081.03%
IPO
1,095.20%
Name
Ascendis Pharma A/S
Chart & performance
P/E
—
P/S
18.70
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.67%
Rev. gr., 5y
150.93%
Revenues
692m
+90.22%
Net income
-219m
L-42.07%
CFO
52m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Key people
Jan Moeller Mikkelsen
President, Chief Executive Officer, Board Member, Executive Director · since 2007
Scott Smith
Chief Financial Officer, Senior Vice President · since 2016
Jens Sigurd Okkels
Senior Vice President - Product Development · since 2019
Juha Punnonen
Senior Vice President - Head of Oncology · since 2018
Lotte Soenderbjerg
Senior Vice President, Chief Administrative Officer · since 2007
Kennett Sprogoee
Senior Vice President - Product Innovation and Research · since 2016
Peter Rasmussen
Principal Accounting Officer, Vice President - Finance · since 2016
Independent Director · since 2017
Lars Holtug
Independent Director · since 2018
Independent Director · since 2016
Headquarters & legal address
Tuborg Boulevard 12
Hellerup 2900
DK
Hellerup 2900
DK
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||